AU7366296A - Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate - Google Patents

Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate

Info

Publication number
AU7366296A
AU7366296A AU73662/96A AU7366296A AU7366296A AU 7366296 A AU7366296 A AU 7366296A AU 73662/96 A AU73662/96 A AU 73662/96A AU 7366296 A AU7366296 A AU 7366296A AU 7366296 A AU7366296 A AU 7366296A
Authority
AU
Australia
Prior art keywords
chemotherapy
prostate
cancer
antisense oligonucleotide
benign hyperplasia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU73662/96A
Inventor
Paul A. Zamecnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Worcester Foundation for Biomedical Research
Original Assignee
Worcester Foundation for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Worcester Foundation for Biomedical Research filed Critical Worcester Foundation for Biomedical Research
Publication of AU7366296A publication Critical patent/AU7366296A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU73662/96A 1995-09-20 1996-09-20 Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate Abandoned AU7366296A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US401895P 1995-09-20 1995-09-20
US004018 1995-09-20
PCT/US1996/015081 WO1997011170A1 (en) 1995-09-20 1996-09-20 Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate

Publications (1)

Publication Number Publication Date
AU7366296A true AU7366296A (en) 1997-04-09

Family

ID=21708727

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73662/96A Abandoned AU7366296A (en) 1995-09-20 1996-09-20 Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate

Country Status (4)

Country Link
EP (1) EP0851919A1 (en)
AU (1) AU7366296A (en)
CA (1) CA2239976A1 (en)
WO (1) WO1997011170A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
ATE526406T1 (en) 1998-03-20 2011-10-15 Commw Scient Ind Res Org CONTROL OF GENE EXPRESSION
CN1213057C (en) * 1998-11-09 2005-08-03 中国人民解放军军事医学科学院放射医学研究所 Structure of antisense oligonucleotide to inhibit activity of telomerase and its application
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
HU230458B1 (en) 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Rna interference mediating small rna molecules
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
WO2004014933A1 (en) 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
AR041407A1 (en) * 2003-09-26 2005-05-18 Nestor Alberto Kerner OLIGONUCLEOTIDOS ANTIANDROGENOS USABLE IN THE TREATMENT OF DERMATOLOGICAL PATHOLOGIES RELATED TO THE ANDROGEN METABOLISM, ITS PHARMACEUTICAL COMPOSITIONS AND THEIR USES AND METHODS OF TREATMENT
US20100286229A1 (en) * 2005-09-30 2010-11-11 Katerina Gurova Modulation of Androgen Receptor for Treatment of Prostate Cancer
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
UA100253C2 (en) 2007-11-26 2012-12-10 Сантаріс Фарма А/С Androgenic receptor lna-antagonists
WO2012065051A1 (en) 2010-11-12 2012-05-18 Enzon Pharmaceuticals, Inc. Compositions and methods for treating androgen receptor dependent disorders including cancers
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
ES2798899T3 (en) 2013-02-25 2020-12-14 Novartis Ag Novel androgen receptor mutation
WO2015066442A1 (en) * 2013-11-01 2015-05-07 Everon Biosciences, Inc. Molecular targets for selective eradication of senescent cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307030B1 (en) * 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
AU4846793A (en) * 1992-09-04 1994-03-29 Baylor College Of Medicine Novel triplex forming oligonucleotides and methods for their use
WO1995011301A1 (en) * 1993-10-19 1995-04-27 The Regents Of The University Of Michigan P53-mediated apoptosis
US5556956A (en) * 1993-11-04 1996-09-17 Board Of Regents, The University Of Texas System Methods and compositions relating to the androgen receptor gene and uses thereof
US6468981B1 (en) * 1994-07-29 2002-10-22 Emory University Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors

Also Published As

Publication number Publication date
EP0851919A1 (en) 1998-07-08
WO1997011170A1 (en) 1997-03-27
CA2239976A1 (en) 1997-03-27

Similar Documents

Publication Publication Date Title
AU7366296A (en) Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
AU5089799A (en) Drug complex for treatment of metastatic prostate cancer
AU1958897A (en) Egf-genistein conjugates for the treatment of cancer
IL189132A0 (en) Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer
AU8298998A (en) System for prostate treatment while preventing urethral constriction
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
EP1176964B8 (en) Uses of et743 for treating cancer
AU4823599A (en) Prostate cancer-associated genes
AU5005697A (en) Methods of preventing breast cancer
AU6229098A (en) Cancer-associated genes
IL136167A0 (en) Conjugates useful in the treatment of prostate cancer
AU5462699A (en) Prostate derived ets factor
AU9018598A (en) Prognostic compositions for prostate cancer and methods of use thereof
AU6537798A (en) Targeted cytolysis of cancer cells
AU7077596A (en) Antisense oligonucleotide chemotherapy for benign hyperplasiaor cancer of the prostate
AU2506499A (en) Cea/nca-based differentiation cancer therapy
GB9828840D0 (en) Prostate cancer associated genes and their products
AU4984696A (en) Capl-specific oligonucleotides and methods of inhibiting metastatic cancer
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
AU4417996A (en) Treatment of prostate cancer
AU7936898A (en) Vectors for treating cancer
AU4644297A (en) Reversal of cancer phenotype by inhibiting expression of prostate tumor inducing gene
ZA961564B (en) Methods of inhibiting ovarian cancer.
AU7130696A (en) Combination of beta-interferon for the treatment of prostate cancer
AU6172896A (en) Melatonin agonists for treating benign prostatic hyperplasia